T2 Biosystems, Inc. (TTOO): Rahul Dhanda , SVP of Corporate Development of T2 Biosystems, Inc. sold 3,589 shares on Jun 30, 2016. The Insider selling transaction was reported by the company on Jul 5, 2016 to the Securities and Exchange Commission. The shares were sold at $8.16 per share for a total value of $29,286.24 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Mar 18, 2016, Rahul Dhanda (SVP of Corporate Development) sold 7,588 shares at $8.02 per share price.On Dec 10, 2015, David B Elsbree (director) purchased 10,000 shares at $9.75 per share price.Also, On Aug 11, 2015, Michael J. Cima (director) purchased 1,000 shares at $14.01 per share price.On Jul 14, 2015, Thomas J. Lowery (Chief Scientific Officer) sold 2,000 shares at $16.03 per share price.
Shares of T2 Biosystems Inc (TTOO) ended Friday, Jul 1, 2016 session in red amid volatile trading. The shares closed down -0.04 points or -0.51% at $7.85 with 1,24,427 shares getting traded. Post opening the session at $7.97, the shares hit an intraday low of $7.42 and an intraday high of $8.0424 and the price vacillated in this range throughout the day. The company has a market cap of $191 M and the number of outstanding shares has been calculated to be 2,42,84,504 shares. The 52-week high of T2 Biosystems Inc is $17.27 and the 52-week low is $7.42.
Company has been under the radar of several Street Analysts.T2 Biosystems Inc is Upgraded by WBB Securities to Buy and the brokerage firm has set the Price Target at $11. Earlier the firm had a rating of Speculative Buy on the company shares. The Rating was issued on Jun 22, 2016.T2 Biosystems Inc is Reiterated by Canaccord Genuity to Buy while Lowering the Price Target of the company shares to $ 12 from a previous price target of $13 . The Rating was issued on Apr 12, 2016.
T2 Biosystems Inc. is an in vitro diagnostics company that has developed a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens biomarkers and other abnormalities in a range of unpurified patient sample types including whole blood plasma serum saliva sputum and urine and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL). The Company’s initial development efforts target sepsis hemostasis and Lyme disease areas of significant unmet medical need. Its platform detects a range of targets including molecular targets such as deoxyribonucleic acid (DNA) immunodiagnostics such as proteins and a range of hemostasis measurements. The initial panels designed to run on T2Dx are T2Candida and T2Bacteria which are focused on identifying life-threatening pathogens associated with sepsis.